Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis.
Sean WassermanRosleine Antilus-SainteNoha AbdelgawadNarineh M OdjourianMelissa CristaldoMaureen DougherFirat KayaMatthew ZimmermanPaolo DentiMartin GengenbacherPublished in: Antimicrobial agents and chemotherapy (2024)
Tuberculous meningitis (TBM) has a high mortality, possibly due to suboptimal therapy. Drug exposure data of antituberculosis agents in the central nervous system (CNS) are required to develop more effective regimens. Rifabutin is a rifamycin equivalently potent to rifampin in human pulmonary tuberculosis. Here, we show that human-equivalent doses of rifabutin achieved potentially therapeutic exposure in relevant CNS tissues in a rabbit model of TBM, supporting further evaluation in clinical trials.
Keyphrases
- pulmonary tuberculosis
- endothelial cells
- cerebrospinal fluid
- clinical trial
- induced pluripotent stem cells
- blood brain barrier
- pluripotent stem cells
- gene expression
- emergency department
- risk factors
- stem cells
- cardiovascular disease
- randomized controlled trial
- bone marrow
- anti inflammatory
- open label
- cell therapy
- smoking cessation
- data analysis
- phase ii